Skip to main content

The evidence for immunotherapy in dermatomyositis and polymyositis: a systematic review

Abstract

Dermatomyositis and polymyositis are rare chronic inflammatory disorders with significant associated morbidity and mortality despite treatment. High-dose corticosteroids in addition to other interventions such as immunosuppressants, immunomodulators, and more recently, biologics are commonly used in clinical practice; however, there are no clear guidelines directing their use. Our objective was to systematically review the evidence for immunotherapy in the treatment of dermatomyositis and polymyositis. Relevant studies were identified through Embase and PubMed database searches. Trials were selected using pre-determined selection criteria and then assessed for quality. Randomized controlled trials and experimental studies without true randomization and including adult patients with definite or probable dermatomyositis or polymyositis were evaluated. Any type of immunotherapy was considered. Clinical improvement, judged by assessment of muscle strength after 6 months, was the primary outcome. Secondary outcomes included IMACS definition of improvement, improvements in patient and physician global scores, physical function, and muscle enzymes. Twelve studies met eligibility criteria. Differences in trial design, quality, and variable reporting of baseline characteristics and outcomes made direct comparison impossible. Although no treatment can be recommended on the basis of this review, improved outcomes were demonstrated with a number of agents including methotrexate, azathioprine, ciclosporin, rituximab, and intravenous immunoglobulin. Plasmapheresis and leukapheresis were of no apparent benefit. More high-quality randomized controlled trials are needed to establish the role of immunosuppressive agents in the treatment of these conditions and the clinical context in which they are most likely to be beneficial.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed). 339:b2700

  2. Higgins JPT GS. Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration; 2011. Available from: www.cochrane-handbook.org

  3. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347

    CAS  Article  PubMed  Google Scholar 

  4. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407

    CAS  Article  PubMed  Google Scholar 

  5. Dalakas MC (1991) Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 325:1487–1498

    CAS  Article  PubMed  Google Scholar 

  6. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12

    CAS  Article  PubMed  Google Scholar 

  7. Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM et al (2004) International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 50:2281–2290

    Article  PubMed  Google Scholar 

  8. Gordon PA, Winer JB, Hoogendijk JE, Choy EH (2012) Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Sys Rev 8:CD003643

    Google Scholar 

  9. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65:314–324

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  10. Ibrahim F, Choy E, Gordon P, Dore CJ, Hakim A, Kitas G, et al. (2014) Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids. Rheumatology

  11. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000

    CAS  Article  PubMed  Google Scholar 

  12. Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL et al (1998) Treatment of refractory myositis. A randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 41:392–399

    CAS  Article  PubMed  Google Scholar 

  13. van de Vlekkert J, Hoogendijk JE, de Haan RJ, Algra A, van der Tweel I, van der Pol WL et al (2010) Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord 20:382–389

    Article  PubMed  Google Scholar 

  14. Miyasaka N, Hara M, Koike T, Saito E, Yamada M, Tanaka Y (2012) Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol 22:382–393

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  15. (2011) A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 70:427-36.

  16. Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG (1980) Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Int Med 92:365–369

    CAS  Article  PubMed  Google Scholar 

  17. Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkov J, Bartunkov J et al (2000) Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 29:95–102

    CAS  Article  PubMed  Google Scholar 

  18. Hollingworth P, de Vere TA, Ansell BM, Platts-Mills T, Gumpel JM, Mertin J et al (1982) Intensive immunosuppression versus prednisolone in the treatment of connective tissue diseases. Ann Rheum Dis 41:557–562

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  19. Amemiya K, Semino-Mora C, Granger RP, Dalakas MC (2000) Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 94:99–104

    CAS  Article  PubMed  Google Scholar 

  20. Bunch TW (1981) Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum 24:45–48

    CAS  Article  PubMed  Google Scholar 

  21. Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R et al (1992) Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 326:1380–1384

    CAS  Article  PubMed  Google Scholar 

  22. Convery FR, Minteer MA, Amiel D, Connett KL (1977) Polyarticular disability: a functional assessment. Arch Phys Med Rehabil 58:494–499

    CAS  PubMed  Google Scholar 

  23. Mahoney FI, Barthel DW (1965) Functional Evaluation: The Barthel Index. Maryland State Med J 14:61–65

    CAS  Google Scholar 

  24. (1996) The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. Arch Neurology. 53:141-7

  25. Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM et al (2014) Predictors of clinical improvement in rituximab-treated refractory adult and juvenile Dermatomyositis and adult polymyositis. Arthritis Rheum 66:740–749

    CAS  Article  Google Scholar 

  26. Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE et al (1993) Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 94:379–387

    CAS  Article  PubMed  Google Scholar 

  27. Miller JWY, Saminaden S, Lecky BRF, Winer JB (2002) Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurol Sci 199(Suppl 1):S53

    Google Scholar 

  28. Ruperto N, Pistorio A (2013) Knupp Feitosa de Oliveira S, Cuttica R, Ravelli A, Fischbach M, et al. A randomized trial in new onset juvenile dermatomyositis: prednisone versus prednisolone plus cyclosporine versus prednisone plus methotrexate. Pediatric. Rheumatology 11(Suppl 2):O19

    Google Scholar 

  29. Tansley SL, Sharp C, McHugh N, Christopher-Stine L, Chinoy H (2014) Developing Standardized Treatment for Adults with Myositis and Different Phenotypes. Rheumatology 53(suppl 1):i127

    Google Scholar 

Download references

Acknowledgments

Conflicts of interest

The authors declare that they have no competing interests.

Funding

Sarah Tansley is supported by a fellowship funded by the Bath Institute for Rheumatic Diseases.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sarah L. Tansley.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOC 49 kb)

ESM 2

(DOC 43 kb)

ESM 3

(DOC 46 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Vermaak, E., Tansley, S.L. & McHugh, N.J. The evidence for immunotherapy in dermatomyositis and polymyositis: a systematic review. Clin Rheumatol 34, 2089–2095 (2015). https://doi.org/10.1007/s10067-015-3059-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-015-3059-y

Keywords

  • Dermatomyositis
  • DMARD
  • Immunotherapy
  • Polymyositis
  • Randomised controlled trial
  • Systematic review